Ipca Laboratories is consolidating its USA generic formulations business by selling rights to nine product approvals for $2.65 million and entire business operations for $10 million to its subsidiary Unichem Laboratories and Unichem Pharmaceuticals, respectively, with no expected change in overall business income.